Recent investigations have focused on the intersection of GLP-1|GIP|GCGR activator therapies and dopamine neurotransmission. While GCGR stimulators are increasingly employed for treating type 2 T2DM, their unexpected effects on motivation circuits, specifically governed by DA pathways, are attrac